Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target

Molecular Cancer Therapeutics

Volumn 14, Issue 1, 2015, Pages 174-182

  Liu, Yang ^a   Kwiatkowski, David J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; ALPHA AMINO N [5,6 DIHYDRO 2 (1 METHYL 1H PYRAZOL 4 YL) 6 OXO 1H PYRROLO[4,3,2 EF][2,3]BENZODIAZEPIN 8 YL]CYCLOHEXANEACETAMIDE; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GEMCITABINE; PROTEIN P21; PROTEIN P53; 3-(CARBAMOYLAMINO)-5-(3-FLUOROPHENYL)-N-(3-PIPERIDYL)THIOPHENE-2-CARBOXAMIDE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CDKN1A PROTEIN, HUMAN; DEOXYCYTIDINE; PF 00477736; PROTEIN KINASE; PYRAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; TP53 PROTEIN, HUMAN; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; FRAMESHIFT MUTATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; IC50; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INDEL MUTATION; MOUSE; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; TREATMENT RESPONSE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MUTATION; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIAZEPINONES; CELL CYCLE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; MICE; MUTATION; PROTEIN KINASES; PYRAZOLES; THIOPHENES; TUMOR SUPPRESSOR PROTEIN P53; UREA; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922162501     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0622-T     Document Type: Article

References (26)

1. Donehower LA. Phosphatases reverse p53-mediated cell cycle checkpoints. Proc Natl Acad Sci U S A 2014;111:7172-3.
2. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
3. WuX, Roth JA, ZhaoH, Luo S, Zheng YL, Chiang S, et al.Cell cycle checkpoints, DNA damage/repair, and lung cancer risk. Cancer Res 2005;65:349-57.
4. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science 1996;274:1664-72.
5. VaziriC, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008.
6. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010;108:73-112.
7. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
8. 2 checkpoints. Proc Natl Acad Sci U S A 2002;99:14795-800.
9. 2 cell cycle checkpoints. Oncogene 2005;24:3786-96.
10. 2-checkpoint inhibitor. Clin Cancer Res 1996;2:791-7.
11. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998;58:3248-53.
12. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275:5600-5.
13. Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN. The radio-sensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60:2108-12.
14. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
15. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17:88-96.
16. King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 2014;32:213-26.
17. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, et al. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 2013;12:1958-67.
18. Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, et al. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin Cancer Res 2013;19:4412-21.
19. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315-22.
20. Sarkar S, Julicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000;60:3862-71.
21. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 2001;20:7453-63.
22. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 2012;122:1541-52.
23. Moon du G, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol 2014;45:1027-35.
24. Chekaluk Y, Wu CL, Rosenberg J, Riester M, Dai Q, Lin S, et al. Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value. PLoS ONE 2013;8:e60927.
25. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res 2009;15:4630-40.
26. Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H. Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 2013;32:577-88.